Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priyanka Mehta

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Viruses|February 28, 2023
Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19Ranit D'Rozario, Deblina Raychaudhuri, Purbita Bandopadhyay, et al.
British Journal of Haematology|November 22, 2022
A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trialFrancis Mussai, Carmela De Santo, Paul Cheng, et al.
Blood|June 25, 2026
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 TrialSteven Knapper, Abin Thomas, Robert K Hills, et al.
British Journal of Haematology|December 27, 2021
A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemiaThomas Coats, Daniel Bean, Aymeric Basset, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> MutationsNigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman, et al.
Vaccines|January 22, 2022
Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare WorkersPratibha Kale, Ekta Gupta, Chhagan Bihari, et al.
British Journal of Haematology|July 8, 2024
CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UKPriyanka Mehta, Victoria Campbell, Jamie Maddox, et al.
Pathogens (Basel, Switzerland)|September 28, 2021
Clinico-Genomic Analysis Reveals Mutations Associated with COVID-19 Disease Severity: Possible Modulation by RNA StructurePriyanka Mehta, Shanmukh Alle, Anusha Chaturvedi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 TrialNigel H Russell, Abin Thomas, Robert K Hills, et al.
Blood Advances|May 12, 2023
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trialJad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Viruses|February 28, 2023
Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19Ranit D'Rozario, Deblina Raychaudhuri, Purbita Bandopadhyay, et al.
British Journal of Haematology|November 22, 2022
A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trialFrancis Mussai, Carmela De Santo, Paul Cheng, et al.
Blood|June 25, 2026
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 TrialSteven Knapper, Abin Thomas, Robert K Hills, et al.
British Journal of Haematology|December 27, 2021
A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemiaThomas Coats, Daniel Bean, Aymeric Basset, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> MutationsNigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman, et al.
Vaccines|January 22, 2022
Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare WorkersPratibha Kale, Ekta Gupta, Chhagan Bihari, et al.
British Journal of Haematology|July 8, 2024
CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UKPriyanka Mehta, Victoria Campbell, Jamie Maddox, et al.
Pathogens (Basel, Switzerland)|September 28, 2021
Clinico-Genomic Analysis Reveals Mutations Associated with COVID-19 Disease Severity: Possible Modulation by RNA StructurePriyanka Mehta, Shanmukh Alle, Anusha Chaturvedi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 TrialNigel H Russell, Abin Thomas, Robert K Hills, et al.
Blood Advances|May 12, 2023
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trialJad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, et al.
Pageof 9